Diabetes and its relationship to pancreatic carcinoma

Pancreas

Volumn 26, Issue 4, 2003, Pages 381-387

  Saruc, Murat ^a   Pour, Parviz M ^b,c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Diabetes; Glucose metabolism; Islet cell; Pancreatic cancer; Surgery

Indexed keywords

TUMOR MARKER;

ADULT; CANCER CELL; DIABETES MELLITUS; DIABETOGENESIS; DISEASE ASSOCIATION; GLUCOSE METABOLISM; HUMAN; HUMAN TISSUE; IMPAIRED GLUCOSE TOLERANCE; MALE; PANCREAS CANCER; PANCREAS CARCINOMA; PANCREAS ISLET CELL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW;

BLOOD GLUCOSE; DIABETES MELLITUS; GLUCOSE INTOLERANCE; HUMANS; ISLETS OF LANGERHANS; MODELS, BIOLOGICAL; PANCREATIC NEOPLASMS;

EID: 0038068046     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006676-200305000-00012     Document Type: Review

References (81)

1. Ahmedin J, Thomas A, Murray T, et al. Cancer Statistics, 2002. CA. 2002;52:23-42.
2. Cooperman AM. Pancreatic cancer: the bigger picture. Surg Clin North Am. 2001;81:557-574.
3. Permert J, Ihse I, Jorfeldt L, et al. Pancreatic cancer is associated with impaired glucose metabolism. Eur J Surg. 1993;159:101-107.
4. Fogar P, Pasquali C, Basso D, et al. Diabetes mellitus in pancreatic cancer follow-up. Anticancer Res. 1994;14:2827-2830.
5. Permert J, Larsson J, Ihse I, et al. Diagnosis of pancreatic cancer. Alteration of glucose metabolism. Int J Pancreatol. 1991;9:113-117.
6. Gullo L, Ancona D, Pezzilli R, et al. Glucose tolerance and insulin secretion in pancreatic cancer. Ital J Gostroenterol. 1993;25:487-489.
7. Ishikawa ONS, Ohigashi H, Imaoka S. Increased secretion of proinsulin in patients with pancreatic cancer. Int J Pancreatol. 1994;16:86.
8. Nakamori S, Ishikawa O, Ohigashi H, et al. Increased blood proinsulin and decreased C-peptide levels in patients with pancreatic cancer. Hepatogastroenterology 1999;46:16-24.
9. Permert J, Larsson J, Fruin AB, et al. Islet hormone secretion in pancreatic cancer patients with diabetes. Pancreas 1997;15:60-68.
10. Larsson J. Relationship between pancreatic cancer and diabetes. Int J Pancreatol. 1994;16:82.
11. Del Favero GBD, Fogar P, Panozzo MP, et al. Alterations of serum hormones in pancreatic cancer patients. Int J Pancreatol. 1994;16:86.
12. Kessler, II. Cancer and diabetes mellitus: A review of the literature. J Chronic Dis. 1971;23:579-600.
13. Silverman DT, Schiffman M, Everhart J, et al. Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br J Cancer. 1999;80:1830-1837.
14. Cuzick J, Babiker AG. Pancreatic cancer, alcohol, diabetes mellitus and gallbladder disease. Int J Cancer. 1989;43:415-421.
15. Brat DJ, Lillemoe KD, Yeo CJ, et al. Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas. Am J Surg Pathol. 1998;22:163-169.
16. Pour P, Kruger FW, Althoff J, et al. Cancer of the pancreas induced in the Syrian golden hamster. Am J Pathol. 1974;76:349-358.
17. Pour PM, Wilson R. Experimental tumors of the pancreas. In: Moossa AR, ed. Tumors of the pancreas. Baltimore/London: Williams & Wilkins; 1980:37-158.
18. Pour PM. Experimental pancreatic cancer. Am J Surg Pathol. 1989;13(Suppl 1):96-103.
19. Pour PM, Egami H, Takiyama Y. Patterns of growth and metastases of induced pancreatic cancer in relation to the prognosis and its clinical implications. Gastroenterology 1991;100:529-536.
20. Pour PM, Tomioka T. Tumors of the pancreas. IARC Sci Publ. 1996;28:149-173.
21. Pour P, Mohr U, Cardesa A, et al. Pancreatic neoplasms in an animal model: morphological, biological, and comparative studies. Cancer 1975;36:379-389.
22. Takiyama Y, Egami H, Pour PM. Expression of human tumor-associated antigens in pancreatic cancer induced in Syrian hamsters. Am J Pathol. 1990;136:707-715.
23. Fujii H, Egami H, Chaney W, et al. Pancreatic ductal adenocarcinomas induced in Syrian hamsters by N-nitrosobis(2-oxopropyl)amine contain a c-Ki-ras oncogene with a point-mutated codon 12. Mol Carcinog. 1990;3:296-301.
24. Erill N, Cuatrecasas M, Sancho FJ, et al. K-ras and p53 mutations in hamster pancreatic ductal adenocarcinomas and cell lines. Am J Pathol. 1996;149:1333-1339.
25. Mogaki M, Hirota M, Chaney WG, et al. Comparison of p53 protein expression and cellular localization in human and hamster pancreatic cancer cell lines. Carcinogenesis 1993;14:2589-2594.
26. Ahren B, Andren-Sandberg A. Glucose tolerance and insulin secretion in experimental pancreatic cancer in the Syrian hamster. Res Exp Med. 1993;193:21-26.
27. Muscarella P, Knobloch TJ, Ulrich AB, et al. Identification and sequencing of the Syrian Golden hamster (Mesocricetus auratus) p16(INK4a) and p15(INK4b) cD-NAs and their homozygous gene deletion in cheek pouch and pancreatic tumor cells. Gene 2001;278:235-243.
28. Pour PM, Weide L, Liu G, et al. Experimental evidence for the origin of ductal-type adenocarcinoma from the islets of Langerhans. Am J Pathol. 1997;150:2167-2180.
29. Bell RH, Jr., McCullough PJ, Pour PM. Influence of diabetes on susceptibility to experimental pancreatic cancer. Am J Surg. 1988;155:159-164.
30. Pour P. Islet cells as a component of pancreatic ductal neoplasms. I. Experimental study: ductular cells, including islet cell precursors, as primary progenitor cells of tumors. Am J Pathol. 1978;90:295-316.
31. Bell RH, Jr., Sayers HJ, Pour PM, et al. Importance of diabetes in inhibition of pancreatic cancer by streptozotocin. J Surg Res. 1989;46:515-519.
32. Pour PM, Patil K. Modification of pancreatic carcinogenesis in the hamster model. X. Effect of streptozotocin. J Natl Cancer Inst. 1983;71:1059-1065.
33. Pour PM, Kazakoff K. Stimulation of islet cell proliferation enhances pancreatic ductal carcinogenesis in the hamster model. Am J Pathol. 1996;149:1017-1025.
34. Schmied BM, Ulrich A, Matsuzaki H, et al. In vitro pancreatic carcinogenesis. Ann Oncol. 1999;10(Suppl 4):41-45.
35. Schmied B, Liu G, Moyer MP, et al. Induction of adenocarcinoma from hamster pancreatic islet cells treated with N-nitrosobis(2-oxopropyl)amine in vitro. Carcinogenesis 1999;20:317-324.
36. Schmied BM, Ulrich AB, Matsuzaki H, et al. Biologic instability of pancreatic cancer xenografts in the nude mouse. Carcinogenesis 2000;21:1121-1127.
37. Birt DF, Julius AD, White LT, et al. Enhancement of pancreatic carcinogenesis in hamsters fed a high-fat diet ad libitum and at a controlled calorie intake. Cancer Res 1989;49:5848-5851.
38. Schneider MB, Matsuzaki H, Haorah J, et al. Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology 2001;120:1263-1270.
39. Bell RH, Pour PM. Induction of pancreatic tumors in genetically non-diabetic but not in diabetic Chinese hamsters. Cancer Lett. 1987;34:221-230.
40. Hirayama T. Cancer epidemiology in Japan. Environ Health Perspect. 1979;32:11-15.
41. Hirayama T. Epidemiology of pancreatic cancer in Japan. Jpn J Clin Oncol. 1989;19:208-215.
42. Hirayama T. Life-style and cancer: from epidemiological evidence to public behavior change to mortality reduction of target cancers. J Natl Cancer Inst Monogr. 1992;12:65-74.
43. Silverman DT, Swanson CA, Gridley G, et al. Dietary and nutritional factors and pancreatic cancer: a case-control study based on direct interviews. J Natl Cancer Inst. 1998;90:1710-1719.
44. Andren-Sandberg A. Alteration of pancreatic hormones in human and experimental pancreatic cancer. Int J Pancreatol. 1994;16:89-90.
45. Permert J, Herrington M, Kazakoff K, et al. Early changes in islet hormone secretion in the hamster pancreatic cancer model. Teratog Carcinog Mutagen. 2001;21:59-67.
46. Ariyama J. Abnormal glucose tolerance in patients with early pancreatic carcinoma. Int J Panc. 1994;16:91.
47. Falconi MS, Bassi C, Zamboni, G et al. Clinicopathological features and treatment of intraductal papillary mucinous tumor of the pancreas. Br J Surg. 2000;88:187-197.
48. Kimura W, Morikane K, Esaki Y, et al. Histological and biological patterns of microscopic ductal adenocarcinomas detected incidentally at autopsy. Cancer 1998;82:1839-1849.
49. Schmied BM, Ulrich AB, Matsuzaki H, et al. Alteration of the Langerhans islets in pancreatic cancer patients. Int J Pancreatol. 2000;28:187-197.
50. Pour PM, Schmied BM, Ulrich AB, et al. Abnormal differentiation of islet cells in pancreatic cancer. Pancreatology 2001;1:110-116.
51. Schmied BM, Ulrich A, Matsuzaki H, et al. Transdifferentiation of human islet cells in a long-term culture. Pancreas 2001;23:157-171.
52. Schmied BM, Liu G, Matsuzaki H, et al. Differentiation of islet cells in long-term culture. Pancreas 2000;20:337-347.
53. Bouwens L. Transdifferentiation versus stem cell hypothesis for the regeneration of islet beta-cells in the pancreas. Microsc Res Tech. 1998;43:332-336.
54. Bouwens L, Kloppel G. Islet cell neogenesis in the pancreas. Virchows Arch. 1996;427:553-560.
55. Kerr-Conte J, Pattou F, Xia Y, et al. Model for human islet neogenesis in vitro from adult pancreatic preparations. Transplant Proc. 1995;27:3268.
56. Yuan S, Paraskevas S, Duguid WP, et al. Phenotypic transformation of isolated human islets in collagen matrix culture. Transplant Proc. 1995;27:3364.
57. Yuan S, Rosenberg L, Paraskevas S, et al. Transdifferentiation of human islets to pancreatic ductal cells in collagen matrix culture. Differentiation 1996;61:67-75.
58. Hunziker E, Stein M. Nestin-expressing cells in the pancreatic islets of Langerhans. Biochem Biophys Res Commun. 2000;271:116-119.
59. Zulewski H, Abraham EJ, Gerlach MJ, et al. Multipotential nestin-positive stem cells isolated from adult pancreatic islets differentiate ex vivo into pancreatic endocrine, exocrine, and hepatic phenotypes. Diabetes 2001;50:521-533.
60. Permert J, Ihse I, Jorfeldt L, et al. Improved glucose metabolism after subtotal pancreatectomy for pancreatic cancer. Br J Surg. 1993;80:1047-1050.
61. Permert J, Adrian TE, Jacobsson P, et al. Is profound peripheral insulin resistance in patients with pancreatic cancer caused by a tumor-associated factor? Am J Surg. 1993;165:61-66; discussion 66-67.
62. Permert J, Larsson J, Westermark GT, et al. Islet amyloid polypeptide in patients with pancreatic cancer and diabetes. N Engl J Med. 1994;330:313-318.
63. Li J, Adrian TE. A factor from pancreatic and colonic cancer cells stimulates glucose uptake and lactate production in myoblasts. Biochem Biophys Res Commun. 1999;260:626-633.
64. Basso D, Valerio A, Seraglia R, et al. Putative pancreatic cancer-associated diabetogenic factor: 2030 MW peptide. Pancreas 2002;24:8-14.
65. Tezel E, Kawase Y, Takeda S, et al. Expression of neural cell adhesion molecule in pancreatic cancer. Pancreas 2001;22:122-125.
66. Kamisawa T, Fukayama M, Tabata I, et al. Neuroendocrine differentiation in pancreatic duct carcinoma special emphasis on duct-endocrine cell carcinoma of the pancreas. Pathol Res Pract. 1996;192:901-908.
67. Pour PM, Permert J, Mogaki M, et al. Endocrine aspects of exocrine cancer of the pancreas: Their patterns and suggested biologic significance. Am J Clin Pathol. 1993;100:223-230.
68. Stridsberg M, Berne C, Sandler S, et al. Inhibition of insulin secretion, but normal peripheral insulin sensitivity, in a patient with a malignant endocrine pancreatic tumour producing high amounts of an islet amyloid polypeptide-like molecule. Diabetologia 1993;36:843-849.
69. Jamal H, Jones PM, Byrne J, et al. Peptide contents of neuropeptide Y, vasoactive intestinal polypeptide, and beta-calcitonin gene-related peptide and their messenger ribonucleic acids after dexamethasone treatment in the isolated rat islets of Langerhans. Endocrinology 1991;129:3372-3380.
70. Ebiou JC, Bulant M, Nicolas P, et al. Pattern of thyrotropin-releasing hormone secretion from the adult and neonatal rat pancreas: comparison with insulin secretion. Endocrinology 1992;130:1371-1379.
71. Borelli MI, Morano MI, Estivariz FE, et al. Glucose induced secretion of ACTH-like products by rat pancreatic islets. Arch Int Physiol Biochem Biophys. 1994;102:17-20.
72. Ordonez NG, Balsaver AM, Mackay B. Mucinous islet cell (amphicrine) carcinoma of the pancreas associated with watery diarrhea and hypokalemia syndrome. Hum Pathol. 1988;19:1458-1461.
73. Laine VJ, Ekfors TO, Gullichsen R, et al. Immunohistochemical characterization of an amphicrine mucinous islet-cell carcinoma of the pancreas: Case report. APHIS. 1992;100:335-340.
74. Schwarts SS, Zeidler A, Moossa AR, et al. A prospective study of glucose tolerance, insulin, C-peptide, and glucagon responses in patients with pancreatic carcinoma. Am J Dig Dis. 1978;23:1107-1114.
75. Amikura K, Kobari M, Matsuno S. The time of occurrence of liver metastasis in carcinoma of the pancreas. Int J Pancreatol. 1995;17:139-146.
76. Standop J, Schneider MB, Ulrich A, et al. The pattern of xenobiotic-metabolising enzymes in the human pancreas. J Toxicol Env Health Part A. 2002;65:1379-1400.
77. Ulrich AB, Schmied BM, Matsuzaki H, et al. Increased expression of glutathione S-transferase-pi in the islets of patients with primary chronic pancreatitis but not secondary chronic pancreatitis. Pancreas 2001;22:388-394.
78. Ulrich AB, Standop J, Schmied BM, et al. Species differences in the distribution of drug-metabolizing enzymes in the pancreas. Toxicol Pathol. 2002;30:247-253.
79. Ishikawa O, Ohhigashi H, Wada A, et al. Morphologic characteristics of pancreatic carcinoma with diabetes mellitus. Cancer 1989;64:1107-1112.
80. Makimattila S, Hietaniemi K, Kiviluoto T, et al. In vivo glucose-stimulated amylin secretion is increased in nondiabetic patients with pancreatic cancer. Metabolism 2001;50:1036-1042.
81. Hayashida CY, Suzuki K, Fujiya H, et al. Morphometrical quantitation of pancreatic endocrine cells in patients with carcinoma of the pancreas. Tohoku J Exp Med. 1983;141:311-322.